The Europe Point of Care Molecular Diagnostics Market should witness market growth of 9.9% CAGR during the forecast period (2023-2030).
Point-of-care molecular diagnostics tests have sped up the identification of cardiovascular disorders to enhance patient care in various clinical settings, such as residences, outpatient clinics, acute care, and healthcare facilities in rural regions. Physicians need real-time input to improve patient care in sensitive care environments like operating rooms, critical care units, emergency rooms, or cardiac catheterization suites. Healthcare experts are looking for ways to replace reactive medicine in outpatient clinics with preventative approaches that involve wearables, apps, and mobile technology as essential elements.
One of the PoC tests kinds that is expanding the quickest is molecular testing, which detects an infectious agent's genetic material. Many tests are used inside and outside hospitals because they are quick, portable, and affordable. Companies like Cepheid, Alere, and Roche Diagnostics have already made their presence known in this market. Companies are designing assays & molecular diagnostic systems for near patient testing due to the growing interest in establishing molecular diagnostic platforms that can be employed in PoC situations.
4.2% of all TB patients with known HIV also had the virus. For the 17 EU/EEA countries that provided data, the notification rate for TB cases in prisons was 217 new cases and relapses per 100,000 prisoners, or a relative risk of 14.7 compared to the general population in the same countries. A total of 67.6% of the 55 337 TB cases recorded in 2017 with a documented treatment outcome in 2018 were successfully treated, while 6.9% resulted in death. Of the 1182 MDR TB patients registered in 2016 but not treated, 49.9% were successfully treated, while 15.7% died. These elements would fuel the expansion of POC testing throughout Europe.
The Germany market dominated the Europe Point of Care Molecular Diagnostics Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $269.8 million by 2030. The UK market is estimated to grow at a CAGR of 9% during (2023-2030). Additionally, The France market would exhibit a CAGR of 10.7% during (2023-2030).
Based on Product & Service, the market is segmented into Assays & Kits, Instruments & Analyzers and Software & Services. Based on End-user, the market is segmented into Physicians Offices, Hospitals & ICUs, Research Institutes and Others. Based on by Technology, the market is segmented into RT-PCR, Isothermal Nucleic Acid Amplification Technology (INAAT) and Others. Based on Application, the market is segmented into Respiratory Diseases, Hospital-acquired Infections, Sexually Transmitted Diseases, Cancer, Hepatitis, Gastrointestinal Disorders and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Bayer AG, F. Hoffmann-La Roche Ltd., Qiagen N.V., Danaher Corporation, Bio-Rad Laboratories, Inc., BioMerieux S.A., Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., and Nova Biomedical Corporation.
Point-of-care molecular diagnostics tests have sped up the identification of cardiovascular disorders to enhance patient care in various clinical settings, such as residences, outpatient clinics, acute care, and healthcare facilities in rural regions. Physicians need real-time input to improve patient care in sensitive care environments like operating rooms, critical care units, emergency rooms, or cardiac catheterization suites. Healthcare experts are looking for ways to replace reactive medicine in outpatient clinics with preventative approaches that involve wearables, apps, and mobile technology as essential elements.
One of the PoC tests kinds that is expanding the quickest is molecular testing, which detects an infectious agent's genetic material. Many tests are used inside and outside hospitals because they are quick, portable, and affordable. Companies like Cepheid, Alere, and Roche Diagnostics have already made their presence known in this market. Companies are designing assays & molecular diagnostic systems for near patient testing due to the growing interest in establishing molecular diagnostic platforms that can be employed in PoC situations.
4.2% of all TB patients with known HIV also had the virus. For the 17 EU/EEA countries that provided data, the notification rate for TB cases in prisons was 217 new cases and relapses per 100,000 prisoners, or a relative risk of 14.7 compared to the general population in the same countries. A total of 67.6% of the 55 337 TB cases recorded in 2017 with a documented treatment outcome in 2018 were successfully treated, while 6.9% resulted in death. Of the 1182 MDR TB patients registered in 2016 but not treated, 49.9% were successfully treated, while 15.7% died. These elements would fuel the expansion of POC testing throughout Europe.
The Germany market dominated the Europe Point of Care Molecular Diagnostics Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $269.8 million by 2030. The UK market is estimated to grow at a CAGR of 9% during (2023-2030). Additionally, The France market would exhibit a CAGR of 10.7% during (2023-2030).
Based on Product & Service, the market is segmented into Assays & Kits, Instruments & Analyzers and Software & Services. Based on End-user, the market is segmented into Physicians Offices, Hospitals & ICUs, Research Institutes and Others. Based on by Technology, the market is segmented into RT-PCR, Isothermal Nucleic Acid Amplification Technology (INAAT) and Others. Based on Application, the market is segmented into Respiratory Diseases, Hospital-acquired Infections, Sexually Transmitted Diseases, Cancer, Hepatitis, Gastrointestinal Disorders and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Bayer AG, F. Hoffmann-La Roche Ltd., Qiagen N.V., Danaher Corporation, Bio-Rad Laboratories, Inc., BioMerieux S.A., Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., and Nova Biomedical Corporation.
Scope of the Study
By Product & Service
- Assays & Kits
- Instruments & Analyzers
- Software & Services Surveillance & Monitoring
By End-user
- Physicians Offices
- Hospitals & ICUs
- Research Institutes
- Others
By Technology
- RT-PCR
- Isothermal Nucleic Acid Amplification Technology (INAAT)
- Others
By Application
- Respiratory Diseases
- Hospital-acquired Infections
- Sexually Transmitted Diseases
- Cancer
- Hepatitis
- Gastrointestinal Disorders
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Bayer AG
- F.Hoffmann-La Roche Ltd.
- Qiagen N.V.
- Danaher Corporation
- Bio-Rad Laboratories, Inc.
- BioMerieux S.A.
- Agilent Technologies, Inc.
- Thermo Fisher Scientific, Inc.
- Nova Biomedical Corporation
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. Europe Point of Care Molecular Diagnostics Market by Product & Service
Chapter 5. Europe Point of Care Molecular Diagnostics Market by End User
Chapter 6. Europe Point of Care Molecular Diagnostics Market by Technology
Chapter 7. Europe Point of Care Molecular Diagnostics Market by Application
Chapter 8. Europe Point of Care Molecular Diagnostics Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- Abbott Laboratories
- Bayer AG
- F. Hoffmann-La Roche Ltd.
- Qiagen N.V.
- Danaher Corporation
- Bio-Rad Laboratories, Inc.
- BioMerieux S.A.
- Agilent Technologies, Inc.
- Thermo Fisher Scientific, Inc.
- Nova Biomedical Corporation
Methodology
LOADING...
